Invitrogen

CD134 (OX40) Monoclonal Antibody (ACT35 (ACT-35)), eBioscience™

CD134 (OX40) Antibody in Flow Cytometry (Flow)

图: 1 / 2

CD134 (OX40) Antibody (14-1347-82) in Flow

Staining of 2-day PHA-L (Product # 00-4977-93)-stimulated normal human peripheral blood cells with 0.125 µg of Mouse IgG1 kappa Isotype Control (Product # 14-4714-85) (blue histogram) or 0.125 µg of CD134 (OX40) Monoclonal Antibody (purple histogram) followed by IgG Polyclonal Antibody, PE (Product # 12-4010-87). Total viable cells were used for analysis, as determined by 7-AAD (Product # 00-6993-50).

Product Image Gallery

产品信息

14-1347-82

应用

建议稀释比

已发表文章

免疫组化 (IHC)

查看2篇已发表文章 2篇已发表文章

免疫组化（石蜡） (IHC (P))

Assay-Dependent

查看1篇已发表文章 1篇已发表文章

免疫组化（冰冻） (IHC (F))

Assay-Dependent

流式细胞分析 (Flow)

1 µg/test

查看3篇已发表文章 3篇已发表文章

产品规格

种属反应

Human

已发表种属

Human

宿主/亚型

Mouse / IgG1, kappa

分类

Monoclonal

类型

Antibody

克隆号

ACT35 (ACT-35)

偶联物

Unconjugated Unconjugated Unconjugated

形式

Liquid

浓度

0.5 mg/mL

纯化类型

Affinity chromatography

保存液

PBS, pH 7.2

内含物

0.09% sodium azide

保存条件

4° C

运输条件

Ambient (domestic); Wet ice (international)

RRID

AB_467479

产品详细信息

Description: The ACT35 monoclonal antibody reacts with human CD134, also known as OX-40. A member of the TNF receptor superfamily, CD134/OX-40 is a 50 kDa type I membrane glycoprotein expressed by activated T lymphocytes. The interaction of CD134 with OX-40L has been implicated in T cell-dependent humoral response, regulation of primary T cell expansion, survival of T cells, size of the memory T cell pool and regulation of tolerance in the CD4^+ T cell compartment.

Applications Reported: This ACT35 (ACT-35) antibody has been reported for use in flow cytometric analysis, immunohistology staining of frozen tissue sections, and immunohistology staining of paraffin embedded tissue sections.

Applications Tested: The ACT35 (ACT-35) antibody has been tested by flow cytometric analysis of 3-day PHA activated human normal human peripheral blood cells. This can be used at less than or equal to 1 µg per test. A test is defined as the amount (µg) of antibody that will stain a cell sample in a final volume of 100 µL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test. It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest.

Purity: Greater than 90%, as determined by SDS-PAGE.

Aggregation: Less than 10%, as determined by HPLC.

Filtration: 0.2 µm post-manufacturing filtered.

靶标信息

OX40 is a protein receptor found on the surface of T cells, a type of white blood cell that plays a crucial role in the immune system. When activated, OX40 promotes the proliferation and survival of T cells, leading to a stronger immune response against cancer cells and infectious agents. OX40 agonists, which are drugs that activate OX40, have shown promising results in preclinical and clinical studies as a potential immunotherapy for cancer. They can enhance the efficacy of other cancer treatments such as chemotherapy and checkpoint inhibitors, and may also have applications in autoimmune diseases and allergies.

仅用于科研。不用于诊断过程。未经明确授权不得转售。

Product References

Immune cell constitution in the tumor microenvironment predicts the outcome in diffuse large B-cell lymphoma.

Haematologica

Autio M,Leivonen SK,Brück O,Mustjoki S,Mészáros Jørgensen J,Karjalainen-Lindsberg ML,Beiske K,Holte H,Pellinen T,Leppä S

14-1347 was used in Immunohistochemistry to characterize immunological profiles of diffuse large B-cell lymphoma, and predict the outcome in response to immunochemotherapy.

Mon Mar 01 00:00:00 UTC 2021

Changes in circulating exosome molecular profiles following surgery/(chemo)radiotherapy: early detection of response in head and neck cancer patients.

British journal of cancer

Theodoraki MN,Laban S,Jackson EK,Lotfi R,Schuler PJ,Brunner C,Hoffmann TK,Whiteside TL,Hofmann L

Published figure using CD134 (OX40) monoclonal antibody (Product # 14-1347-82) in Flow Cytometry

Wed Dec 01 00:00:00 UTC 2021

ICOS⁺ Foxp3⁺ TILs in gastric cancer are prognostic markers and effector regulatory T cells associated with Helicobacter pylori.

International journal of cancer

Nagase H,Takeoka T,Urakawa S,Morimoto-Okazawa A,Kawashima A,Iwahori K,Takiguchi S,Nishikawa H,Sato E,Sakaguchi S,Mori M,Doki Y,Wada H

14134782 was used in flow cytometry to establish the T Cell receptor-inducible costimulator as a promising target for direct T regulatory cell-targeting therapeutic agents for gastric cancer

Wed Feb 01 00:00:00 UTC 2017

Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma.

NPJ genomic medicine

Reuben A,Spencer CN,Prieto PA,Gopalakrishnan V,Reddy SM,Miller JP,Mao X,De Macedo MP,Chen J,Song X,Jiang H,Chen PL,Beird HC,Garber HR,Roh W,Wani K,Chen E,Haymaker C,Forget MA,Little LD,Gumbs C,Thornton RL,Hudgens CW,Chen WS,Austin-Breneman J,Sloane RS,Nezi L,Cogdill AP,Bernatchez C,Roszik J,Hwu P,Woodman SE,Chin L,Tawbi H,Davies MA,Gershenwald JE,Amaria RN,Glitza IC,Diab A,Patel SP,Hu J,Lee JE,Grimm EA,Tetzlaff MT,Lazar AJ,Wistuba II,Clise-Dwyer K,Carter BW,Zhang J,Futreal PA,Sharma P,Allison JP,Cooper ZA,Wargo JA

14-1347 was used in Immunohistochemistry on paraffin embedded tissues to yield insight into differential therapeutic responses to targeted therapy and immune checkpoint blockade in melanoma, and have key translational implications in the age of precision medicine.

Sat Jan 02 00:00:00 UTC 2021

Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma.

Oncoimmunology

Cooper ZA,Reuben A,Spencer CN,Prieto PA,Austin-Breneman JL,Jiang H,Haymaker C,Gopalakrishnan V,Tetzlaff MT,Frederick DT,Sullivan RJ,Amaria RN,Patel SP,Hwu P,Woodman SE,Glitza IC,Diab A,Vence LM,Rodriguez-Canales J,Parra ER,Wistuba II,Coussens LM,Sharpe AH,Flaherty KT,Gershenwald JE,Chin L,Davies MA,Clise-Dwyer K,Allison JP,Sharma P,Wargo JA

14-1347 was used in Immunohistochemistry to suggest that antitumor immune responses should be assessed when considering therapeutic options for patients with melanoma.

Tue Mar 01 00:00:00 UTC 2016

Selective targeting of Toll-like receptors and OX40 inhibit regulatory T-cell function in follicular lymphoma.

International journal of cancer

Voo KS,Foglietta M,Percivalle E,Chu F,Nattamai D,Harline M,Lee ST,Bover L,Lin HY,Baladandayuthapani V,Delgado D,Luong A,Davis RE,Kwak LW,Liu YJ,Neelapu SS

14-1347 was used in Flow cytometry/Cell sorting to assess novel adjuvants that may enhance the efficacy of antitumour immunotherapeutic strategies by inhibiting Tregs.

Mon Dec 15 00:00:00 UTC 2014

生物信息学

蛋白别名: ACT35 antigen; ATC35 antigen; CD134; CD134 antigen; lymphoid activation antigene ACT35; OX40 antigen; OX40 cell surface antigen; OX40 homologue; OX40L receptor; TAX transcriptionally-activated glycoprotein 1 receptor; tax-transcriptionally activated glycoprotein 1 receptor; Tumor necrosis factor receptor superfamily member 4; tumor necrosis factor receptor superfamily, member 4

查看更多收起

基因别名: ACT35; CD134; IMD16; OX40; TNFRSF4; TXGP1L

查看更多收起

UniProt ID: (Human) P43489

查看更多收起

Entrez Gene ID: (Human) 7293

查看更多收起

功能

virus receptor activity tumor necrosis factor-activated receptor activity transmembrane signal receptor

参与通路